Milestone Pharmaceuticals (MIST) Price Targets Raised by Jefferies Amid PDUFA Confidence

Jefferies has raised the price target for Milestone Pharmaceuticals (NASDAQ:MIST) to $2 from $1, citing continued confidence in its PDUFA and a planned product launch early next year. The company expects meaningful sales to start in Q1 next year, with 60 representatives targeting up to 15,000 high-volume prescribers. Milestone Pharmaceuticals is developing Etripamil for paroxysmal supraventricular tachycardia treatment.